arrow
B

Bjørn Naume

Oslo University Hospital
H指数:59
被引数:1.3万

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Cost-effectiveness of Prosigna for Adjuvant Treatment Decisions in Early Breast Cancer: Healthcare Sector and Societal Perspectives

Prosigna在早期乳腺癌辅助治疗决策中的成本效益:卫生保健部门和 societal perspectives

2025-04-150
PREAI
Circulating tumor cells in metastatic breast cancer patients treated with immune checkpoint inhibitors - a biomarker analysis of the ALICE and ICON trials

免疫检查点抑制剂治疗的转移性乳腺癌患者的循环肿瘤细胞-ALICE和ICON试验的生物标志物分析

2024-07-085
OAAI
Impact of Prosigna test on adjuvant treatment decision in lymph nodenegative early breast cancer d a prospective national multicentre study (EMIT-1)
2024-06-011
OAAI
Ipilimumab and nivolumab combined with anthracycline-based chemotherapy in metastatic hormone receptor-positive breast cancer: a randomized phase 2b trial

Ipilimumab和nivolumab联合蒽环类化疗治疗转移性激素受体阳性乳腺癌: 一项随机2b期试验

2024-01-193
OAAI
Radium-223 in women with hormone receptor-positive bone-metastatic breast cancer receiving endocrine therapy: pooled analysis of two international, phase 2, randomized, double-blind, placebo-controlled trials
2023-12-204
OAAI
OPTIMA, a prospective randomized trial to validate the clinical utility and cost-effectiveness of gene expression test-directed chemotherapy decisions in high clinical risk early breast cancer
2023-03-011
PRE
Atezolizumab plus anthracycline-based chemotherapy in metastatic triple-negative breast cancer: the randomized, double-blind phase 2b ALICE trial
2022-12-0841
OAAI
RNA sequencing-based single sample predictors of molecular subtype and risk of recurrence for clinical assessment of early-stage breast cancer
2022-08-1635
OAAI
Disseminated tumour cells from the bone marrow of early breast cancer patients: Results from an international pooled analysis
2021-09-0131
PRE